The Fort Worth Press - Medical Care Technologies Inc. (OTCID:MDCE) Continues Accepting Human Image Submissions for Melanoma Scan Beta Testing

USD -
AED 3.672501
AFN 65.000137
ALL 81.297901
AMD 362.796361
ANG 1.789785
AOA 917.999705
ARS 1545.680346
AUD 1.453224
AWG 1.8
AZN 1.698478
BAM 1.751128
BBD 2.022649
BDT 125.223838
BGN 1.747831
BHD 0.378911
BIF 3004.498959
BMD 1
BND 1.283972
BOB 11.911754
BRL 5.582901
BSD 1.004405
BTN 94.392415
BWP 13.779334
BYN 3.007212
BYR 19600
BZD 2.019984
CAD 1.419505
CDF 2315.000078
CHF 0.825594
CLF 0.025004
CLP 984.097417
CNY 6.67035
CNH 6.67347
COP 3307.76
CRC 454.299234
CUC 1
CUP 24.105328
CVE 98.725915
CZK 21.803604
DJF 178.828163
DKK 6.69303
DOP 60.919432
DZD 136.502003
EGP 53.316906
ERN 15
ETB 161.150546
EUR 0.89538
FJD 2.25845
FKP 0.745155
GBP 0.748965
GEL 2.60138
GGP 0.745155
GHS 11.761335
GIP 0.745155
GMD 73.999827
GNF 8897.961742
GTQ 7.674952
GYD 210.461285
HKD 7.845505
HNL 26.999889
HRK 6.76901
HTG 131.649514
HUF 326.181497
IDR 18137
ILS 3.18295
IMP 0.745155
INR 93.70785
IQD 1522.620849
IRR 1906074.999586
ISK 122.502706
JEP 0.745155
JMD 159.406925
JOD 0.708988
JPY 158.807499
KES 129.930342
KGS 87.449802
KHR 4096.250699
KMF 441.999677
KPW 899.999961
KRW 1334.780493
KWD 0.31105
KYD 0.836967
KZT 448.414795
LAK 22606.912791
LBP 89940.147639
LKR 333.792943
LRD 170.741971
LSL 16.465622
LTL 2.95274
LVL 0.60489
LYD 6.438471
MAD 9.797561
MDL 18.047927
MGA 4589.999876
MKD 55.115995
MMK 2099.696522
MNT 3601.450067
MOP 8.115302
MRU 40.517153
MUR 46.919747
MVR 15.385115
MWK 1741.621825
MXN 18.60104
MYR 4.072966
MZN 63.89885
NAD 16.46599
NGN 1346.029846
NIO 36.750073
NOK 9.497205
NPR 151.027187
NZD 1.78162
OMR 0.384497
PAB 1.004405
PEN 3.422926
PGK 4.49825
PHP 63.147502
PKR 277.777828
PLN 3.93585
PYG 6199.364397
QAR 3.661271
RON 4.785007
RSD 105.338002
RUB 83.200043
RWF 1486.001307
SAR 3.757016
SBD 8.090747
SCR 13.985569
SDG 601.49623
SEK 9.8658
SGD 1.28116
SHP 0.749316
SLE 22.901353
SLL 20969.504398
SOS 574.004602
SRD 37.545985
STD 20697.981008
STN 21.935911
SVC 8.78869
SYP 13001.999685
SZL 16.470883
THB 33.600993
TJS 9.230273
TMT 3.5
TND 3.000294
TOP 2.40776
TRY 50.226399
TTD 6.811772
TWD 32.854994
TZS 2642.502955
UAH 45.682386
UGX 4098.023064
UYU 40.639633
UZS 12026.931445
VES 900.490505
VND 25627
VUV 120.001108
WST 2.780103
XAF 587.330878
XAG 0.019058
XAU 0.000247016961
XCD 2.70255
XCG 1.810116
XDR 0.707052
XOF 587.330878
XPF 107.249716
YER 236.502208
ZAR 16.50711
ZMK 9001.196363
ZMW 20.461036
ZWL 321.999592
SSP 5745.814556
MXV 2.090552
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Medical Care Technologies Inc. (OTCID:MDCE) Continues Accepting Human Image Submissions for Melanoma Scan Beta Testing
Medical Care Technologies Inc. (OTCID:MDCE) Continues Accepting Human Image Submissions for Melanoma Scan Beta Testing

Medical Care Technologies Inc. (OTCID:MDCE) Continues Accepting Human Image Submissions for Melanoma Scan Beta Testing

Volunteer Intake Remains Open as the Company Prepares to Post Updated Evaluation Results on Its Corporate Website in the Coming Weeks

Text size:

MESA, AZ / ACCESS Newswire / October 8, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that MDCE Melanoma Scan Beta continues to accept human-submitted images for internal testing, and that updated evaluation results are expected to be posted on the Company's corporate website in the coming weeks.

Investors and interested participants can follow the Company at https://www.medicalcaretechnologies.com.

The program is already past first collection. MDCE announced volunteer intake on September 4, receipt of the first human-submitted datasets on September 16, the start of internal review on September 23, and first-pass results on September 29. That first pass indicated that real-world user photographs could move through image-quality scoring, body-map registration, and change-over-time comparison. Intake staying open is how the next evaluation pass gets built.

Until the volunteer phase, model work centered on public dermatology archives, including HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. Human-submitted images add the variables those archives do not fully capture: lighting, device type, distance, angle, compression, and everyday image quality. Additional submissions are intended to widen that test set so later review is not limited to the first cohort.

The coming website update is expected to cover the same three technical layers already in evaluation:

  • Image intake and quality scoring - whether new user photographs can be received and separated into usable and held-out samples
  • Body-map registration - whether images can be placed on the interactive body map so the same skin area can be found again
  • Change-over-time comparison - whether successive images of a mapped area can be organized for visual review

MDCE Melanoma Scan Beta is being developed as an AI-assisted imaging and body-map monitoring application intended to help users catalog visible skin images and review the same mapped area across sessions. The platform remains in beta-stage development. It has not received regulatory clearance and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. It is not a substitute for professional medical advice, screening, or evaluation by a qualified healthcare provider.

"The first datasets proved the workflow can run on photographs people actually take," said Marshall Perkins, CEO of Medical Care Technologies. "We are still accepting submissions because a stronger test set makes a stronger readout. Investors should look for that next update on the corporate site in the coming weeks."

Volunteer participation is not a clinical diagnosis program and is not a clinical efficacy trial. Any concern about a skin change should be reviewed by a licensed clinician. References to testing describe internal technical evaluation of image handling, mapping, and comparison.

About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTCID:MDCE) is a diversified technology company focused on the development and commercialization of artificial intelligence-powered applications spanning health, wellness, nutrition, lifestyle, and enterprise imaging analysis solutions. Visit: https://www.medicalcaretechnologies.com

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding continued image collection and planned publication of evaluation updates. Forward-looking statements are based on current expectations and assumptions, and actual results may differ materially due to various risks and uncertainties. The company undertakes no obligation to update these statements except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.

Contact Information:
Medical Care Technologies Inc.
1910 S. Stapley Drive, Suite 221, Mesa, AZ 85204
Phone: +1 (480) 645-0750
Email: [email protected]
Website: https://www.medicalcaretechnologies.com

SOURCE: Medical Care Technologies Inc.



View the original press release on ACCESS Newswire

W.Lane--TFWP